FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135371333> ?p ?o ?g. }

• W3135371333 endingPage "29" @default.
• W3135371333 startingPage "21" @default.
• W3135371333 abstract "BACKGROUND: Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that has demonstrated efficacy in metastatic renal-cell carcinoma (mRCC) randomized trials. OBJECTIVE: To explore the real-world effectiveness of cabozantinib in pretreated patients with mRCC, including patients who progressed on immune-oncology checkpoint inhibitor (ICI) therapy. METHODS: Using the Canadian Kidney Cancer information system (CKCis), patients with mRCC treated with cabozantinib monotherapy as second-line or later from January 1, 2011 to September 1, 2019 were identified. Patients were stratified based on line of cabozantinib received. We reported overall survival (OS), time to treatment failure (TTF) and disease control rate (DCR). Prognostic variables were analyzed using multivariable analysis. RESULTS: 157 patients received cabozantinib (median TTF 8.0 months; median OS 15.8 months): 37 (24%) in the second line (median TTF 10.4 months; median OS 18.9 months) 66 (42%) in third line (median TTF 5.9 months; median OS 13.3 months) and 54 (34%) in either 4th or 5th line (median TTF 9.4 months; median OS 16.8 months). One hundred sixteen patients (74%) received cabozantinib after prior ICI therapy (median TTF of 7.6 months; median OS of 15.8 months). DCR in all patients was 63% with 46%, 65% and 72% in 2nd line, 3rd line and 4th/5th line patients respectively. DCR in patients who received cabozantinib after prior ICI therapy was 64%. CONCLUSIONS: Cabozantinib is effective in a real-world, unselected population of mRCC patients, including in those who have progressed on prior ICI therapy, and in those exposed to multiple lines of therapy." @default.
• W3135371333 created "2021-03-15" @default.
• W3135371333 creator A5007063312 @default.
• W3135371333 creator A5013185325 @default.
• W3135371333 creator A5018558510 @default.
• W3135371333 creator A5022267545 @default.
• W3135371333 creator A5028194267 @default.
• W3135371333 creator A5028436511 @default.
• W3135371333 creator A5028838961 @default.
• W3135371333 creator A5034541004 @default.
• W3135371333 creator A5042123586 @default.
• W3135371333 creator A5054206895 @default.
• W3135371333 creator A5061327271 @default.
• W3135371333 creator A5069016257 @default.
• W3135371333 creator A5077514210 @default.
• W3135371333 creator A5082859060 @default.
• W3135371333 creator A5087150696 @default.
• W3135371333 date "2021-03-23" @default.
• W3135371333 modified "2023-10-16" @default.
• W3135371333 title "Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)" @default.
• W3135371333 cites W1966034643 @default.
• W3135371333 cites W1980875076 @default.
• W3135371333 cites W2041019655 @default.
• W3135371333 cites W2091632549 @default.
• W3135371333 cites W2100945326 @default.
• W3135371333 cites W2111378135 @default.
• W3135371333 cites W2113322173 @default.
• W3135371333 cites W2135139265 @default.
• W3135371333 cites W2146850908 @default.
• W3135371333 cites W2222086386 @default.
• W3135371333 cites W2237254160 @default.
• W3135371333 cites W2415950182 @default.
• W3135371333 cites W2514283099 @default.
• W3135371333 cites W2558408743 @default.
• W3135371333 cites W2591983966 @default.
• W3135371333 cites W2614480329 @default.
• W3135371333 cites W2735520635 @default.
• W3135371333 cites W2782007611 @default.
• W3135371333 cites W2782594419 @default.
• W3135371333 cites W2792937256 @default.
• W3135371333 cites W2802168781 @default.
• W3135371333 cites W2889646458 @default.
• W3135371333 cites W2891078672 @default.
• W3135371333 cites W2911812451 @default.
• W3135371333 cites W2913745075 @default.
• W3135371333 cites W2916100539 @default.
• W3135371333 cites W2997000594 @default.
• W3135371333 cites W3006846003 @default.
• W3135371333 cites W3036595858 @default.
• W3135371333 cites W3088188638 @default.
• W3135371333 cites W3107817192 @default.
• W3135371333 cites W2791480481 @default.
• W3135371333 doi "https://doi.org/10.3233/kca-210110" @default.
• W3135371333 hasPublicationYear "2021" @default.
• W3135371333 type Work @default.
• W3135371333 sameAs 3135371333 @default.
• W3135371333 citedByCount "1" @default.
• W3135371333 countsByYear W31353713332022 @default.
• W3135371333 crossrefType "journal-article" @default.
• W3135371333 hasAuthorship W3135371333A5007063312 @default.
• W3135371333 hasAuthorship W3135371333A5013185325 @default.
• W3135371333 hasAuthorship W3135371333A5018558510 @default.
• W3135371333 hasAuthorship W3135371333A5022267545 @default.
• W3135371333 hasAuthorship W3135371333A5028194267 @default.
• W3135371333 hasAuthorship W3135371333A5028436511 @default.
• W3135371333 hasAuthorship W3135371333A5028838961 @default.
• W3135371333 hasAuthorship W3135371333A5034541004 @default.
• W3135371333 hasAuthorship W3135371333A5042123586 @default.
• W3135371333 hasAuthorship W3135371333A5054206895 @default.
• W3135371333 hasAuthorship W3135371333A5061327271 @default.
• W3135371333 hasAuthorship W3135371333A5069016257 @default.
• W3135371333 hasAuthorship W3135371333A5077514210 @default.
• W3135371333 hasAuthorship W3135371333A5082859060 @default.
• W3135371333 hasAuthorship W3135371333A5087150696 @default.
• W3135371333 hasBestOaLocation W31353713331 @default.
• W3135371333 hasConcept C121608353 @default.
• W3135371333 hasConcept C126322002 @default.
• W3135371333 hasConcept C126894567 @default.
• W3135371333 hasConcept C141071460 @default.
• W3135371333 hasConcept C143998085 @default.
• W3135371333 hasConcept C2777472916 @default.
• W3135371333 hasConcept C2778820342 @default.
• W3135371333 hasConcept C2781064419 @default.
• W3135371333 hasConcept C2781068499 @default.
• W3135371333 hasConcept C2908647359 @default.
• W3135371333 hasConcept C71924100 @default.
• W3135371333 hasConcept C99454951 @default.
• W3135371333 hasConceptScore W3135371333C121608353 @default.
• W3135371333 hasConceptScore W3135371333C126322002 @default.
• W3135371333 hasConceptScore W3135371333C126894567 @default.
• W3135371333 hasConceptScore W3135371333C141071460 @default.
• W3135371333 hasConceptScore W3135371333C143998085 @default.
• W3135371333 hasConceptScore W3135371333C2777472916 @default.
• W3135371333 hasConceptScore W3135371333C2778820342 @default.
• W3135371333 hasConceptScore W3135371333C2781064419 @default.
• W3135371333 hasConceptScore W3135371333C2781068499 @default.
• W3135371333 hasConceptScore W3135371333C2908647359 @default.
• W3135371333 hasConceptScore W3135371333C71924100 @default.

• next